Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × FED × avelumab × Clear all

Phase

Status

Sponsor Class

OTHER 25 INDUSTRY 24 NIH 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1

Interventions

stenoparib 1 sargramostim 1 poly ICLC 1 pembrolizumab 1 copanlisib 1 avelumab 1 Yoga 1 Temozolomide 1 PM 01183 1 Immunoglobulins, Intravenous 1 Hydroxychloroquine 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Ethiodized Oil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡